What is BPS Bioscience?
BPS Bioscience operates as a specialized provider of high-precision tools and solutions essential for modern drug discovery. The company maintains a robust portfolio that spans immunotherapy, CAR T-cell therapy, and epigenetics, providing researchers with the biochemical assay kits, cell lines, and virus-based tools necessary for complex therapeutic development. Beyond its product catalog, the firm distinguishes itself through custom development services and compound screening, acting as a vital partner for organizations aiming to achieve breakthroughs in medicine. Their commitment to quality control and scientific rigor has established them as a trusted entity for academic and commercial laboratories globally.
How much funding has BPS Bioscience raised?
BPS Bioscience has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in BPS Bioscience
PPP
Public-Private Partnership
What's next for BPS Bioscience?
With the successful acquisition of this latest financing, BPS Bioscience is poised to enter a new phase of expansion. The strategic allocation of these funds will likely focus on scaling production capacity for their proprietary assay kits and deepening their investment in R&D for emerging therapeutic modalities. As the demand for specialized immunotherapy tools continues to rise, the company is expected to leverage its strengthened balance sheet to capture additional market share and potentially broaden its service offerings in the custom screening sector. This late-stage growth trajectory suggests a focus on long-term sustainability and the solidification of their infrastructure to support the next generation of pharmaceutical innovation.
See full BPS Bioscience company page
